cbp146 Inhibitors
Cbp146, also known as BAZ1A in humans, plays a crucial role in the intricate processes of chromatin remodeling and subsequent gene expression. As a component of the chromatin accessibility complex, it modulates the structure of chromatin, thereby influencing the transcriptional landscape of the cell. The modulation of chromatin structure is a pivotal step in the regulation of gene expression, allowing for the precise timing and localization of transcriptional activity in response to various cellular signals and environmental conditions. The protein cbp146, with its bromodomain, is particularly tailored to read epigenetic marks, specifically the acetylation of lysine residues on histone tails, which serves as a signal for gene activation. By interpreting these epigenetic cues, cbp146 facilitates the orchestration of a dynamic chromatin environment, which is essential for the correct expression of genes and the maintenance of cellular identity and function.
In the pursuit of understanding the regulation of gene expression, numerous chemicals have been identified that can potentially inhibit the activity of proteins such as cbp146. These inhibitors generally target the epigenetic mechanisms of action or the protein domains essential for the proper function of cbp146. Compounds like JQ1 and I-BET762 are designed to bind to the bromodomain of cbp146, potentially preventing it from interacting with acetylated histones, an interaction that is necessary for the transcription of certain genes. This can lead to a reduction in the expression of cbp146 itself, as well as the genes it regulates. Other chemicals, including histone deacetylase inhibitors such as Vorinostat (SAHA) and Entinostat (MS-275), induce hyperacetylation of histone proteins, which could counterintuitively lead to a repression of cbp146 expression by altering the epigenetic landscape. DNA methyltransferase inhibitors like 5-Azacytidine and Decitabine exert their potential inhibitory effects by inducing DNA demethylation, which may repress the transcription of the cbp146 gene. Each of these chemicals interacts with the cell's epigenetic machinery in a way that could lead to the downregulation of cbp146, thereby offering valuable insights into the complex regulation of gene expression.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
(±)-JQ1 | 1268524-69-1 | sc-472932 sc-472932A | 5 mg 25 mg | $231.00 $863.00 | 1 | |
JQ1 competitively binds to the acetyl-lysine recognition pocket of bromodomains, potentially leading to the downregulation of cbp146 by preventing the protein from interacting with acetylated histones. | ||||||
GSK 525762A | 1260907-17-2 | sc-490339 sc-490339A sc-490339B sc-490339C sc-490339D | 5 mg 10 mg 50 mg 100 mg 1 g | $300.00 $540.00 $940.00 $1680.00 $5900.00 | ||
By binding to the bromodomains, I-BET762 could prevent the recruitment of transcriptional machinery to the cbp146 gene locus, leading to decreased transcription and subsequent reduced expression of cbp146. | ||||||
PFI-1 | 1403764-72-6 | sc-478504 | 5 mg | $98.00 | ||
PFI-1 inhibits the interaction between bromodomain-containing proteins and chromatin, which could result in decreased expression of cbp146 by disrupting its normal chromatin-mediated regulation. | ||||||
RVX 208 | 1044870-39-4 | sc-472700 | 10 mg | $340.00 | ||
RVX-208 is designed to bind to bromodomains, and by doing so, it could decrease the expression of cbp146 by hampering the protein's ability to exert its role in chromatin remodeling. | ||||||
CPI-203 | 1446144-04-2 | sc-501599 | 1 mg | $170.00 | ||
CPI-203 targets the BET bromodomains to inhibit their function, which could lead to the downregulation of cbp146 by interfering with the chromatin-based control mechanisms critical for its expression. | ||||||
MS-275 | 209783-80-2 | sc-279455 sc-279455A sc-279455B | 1 mg 5 mg 25 mg | $24.00 $90.00 $212.00 | 24 | |
MS-275 selectively inhibits class I histone deacetylases, leading to increased acetylation of histones, which could result in the repression of cbp146 gene expression by altering the chromatin landscape. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $133.00 $275.00 | 37 | |
Suberoylanilide Hydroxamic Acid inhibits the enzymatic activity of histone deacetylases, which could lead to hyperacetylated chromatin states and consequent repression of cbp146 gene expression. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
5-Azacytidine acts as a DNA methyltransferase inhibitor, leading to DNA demethylation that could repress cbp146 gene expression by enabling the transcriptional silencing of its genomic region. | ||||||
5-Aza-2′-Deoxycytidine | 2353-33-5 | sc-202424 sc-202424A sc-202424B | 25 mg 100 mg 250 mg | $218.00 $322.00 $426.00 | 7 | |
5-Aza-2′-Deoxycytidine causes hypomethylation of DNA, which may lead to the repression of cbp146 expression by altering gene methylation status and thus changing gene expression patterns. | ||||||
Panobinostat | 404950-80-7 | sc-208148 | 10 mg | $200.00 | 9 | |
Panobinostat, as a broad-spectrum histone deacetylase inhibitor, can induce hyperacetylation of histones, potentially leading to the repression of cbp146 expression by modifying the epigenetic state of DNA. | ||||||